March 5 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' SPRY.O nasal spray for severe allergic reactions in patients who weigh between 15 to 30 kilograms, the company said on Wednesday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.